Kamilia Smith, MD, FACOG, NCMP, discusses how shared decision-making approaches combined with emerging neurokinin-targeted ...

A man with prostate cancer who was receiving androgen blockade had a substantial reduction in the frequency of hot flashes with the use of fezolinetant.

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

Innovative research has provided compelling evidence that perceived stress can directly trigger the relapse of psoriatic skin ...

Vasomotor symptoms are a common problem in women with HR-positive breast cancer receiving anti-cancer therapy.

(RTTNews) - Bayer Aktiengesellschaft (BAYRY.PK), Thursday announced that Elinzanetant, a non-hormonal drug, has met all primary and second endpoints in the Phase III study OASIS 4, investigating the ...

The drug's development was funded by Novo Nordisk, the maker of popular semaglutide drugs like Ozempic and Wegovy. While ...

rounding out a trio of phase 3 trials that the German pharma group has been running in support of the oral neurokinin 1, 3 antagonist as a treatment for VMS. In the study, elinzanetant ...

After hours: January 10 at 7:19:09 PM EST Loading Chart for HRTX ...